BRPI0814252A8 - composição farmacêutica aquosa compreendendo natalizumab - Google Patents

composição farmacêutica aquosa compreendendo natalizumab

Info

Publication number
BRPI0814252A8
BRPI0814252A8 BRPI0814252A BRPI0814252A BRPI0814252A8 BR PI0814252 A8 BRPI0814252 A8 BR PI0814252A8 BR PI0814252 A BRPI0814252 A BR PI0814252A BR PI0814252 A BRPI0814252 A BR PI0814252A BR PI0814252 A8 BRPI0814252 A8 BR PI0814252A8
Authority
BR
Brazil
Prior art keywords
natalizumab
pharmaceutical composition
aqueous pharmaceutical
vla
relates
Prior art date
Application number
BRPI0814252A
Other languages
English (en)
Inventor
Maloney Kevin
Original Assignee
Biogen Idec Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Ma Inc filed Critical Biogen Idec Inc
Publication of BRPI0814252A2 publication Critical patent/BRPI0814252A2/pt
Publication of BRPI0814252A8 publication Critical patent/BRPI0814252A8/pt
Publication of BRPI0814252B1 publication Critical patent/BRPI0814252B1/pt
Publication of BRPI0814252B8 publication Critical patent/BRPI0814252B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

composição farmacêutica aquosa compreendendo natalizumab a presente invenção refere-se às formulações do anticorpo de ligação vla-4.
BRPI0814252A 2007-06-14 2008-06-13 composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia BRPI0814252B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94407607P 2007-06-14 2007-06-14
PCT/US2008/066928 WO2008157356A2 (en) 2007-06-14 2008-06-13 Antibody formulations

Publications (4)

Publication Number Publication Date
BRPI0814252A2 BRPI0814252A2 (pt) 2015-04-14
BRPI0814252A8 true BRPI0814252A8 (pt) 2019-01-29
BRPI0814252B1 BRPI0814252B1 (pt) 2019-12-10
BRPI0814252B8 BRPI0814252B8 (pt) 2021-05-25

Family

ID=39956053

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814252A BRPI0814252B8 (pt) 2007-06-14 2008-06-13 composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia

Country Status (24)

Country Link
US (3) US20080311119A1 (pt)
EP (2) EP2170390B1 (pt)
JP (2) JP2010529999A (pt)
CN (2) CN103977404A (pt)
AR (2) AR067011A1 (pt)
AU (1) AU2008266051B2 (pt)
BR (1) BRPI0814252B8 (pt)
CA (1) CA2690382A1 (pt)
CY (1) CY1121208T1 (pt)
DK (1) DK2170390T3 (pt)
EA (1) EA020456B1 (pt)
ES (1) ES2707815T3 (pt)
HR (1) HRP20182146T1 (pt)
HU (1) HUE041555T2 (pt)
IL (1) IL202648B (pt)
LT (1) LT2170390T (pt)
MX (2) MX2009013593A (pt)
NZ (2) NZ595526A (pt)
PL (1) PL2170390T3 (pt)
PT (1) PT2170390T (pt)
SI (1) SI2170390T1 (pt)
TR (1) TR201820837T4 (pt)
TW (1) TWI614028B (pt)
WO (1) WO2008157356A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
CA2765220A1 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1200718A1 (en) * 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
PE20150190A1 (es) * 2012-06-21 2015-02-13 Ucb Pharma Sa Formulacion farmaceutica
IN2015KN00005A (pt) 2012-07-09 2015-07-31 Coherus Biosciences Inc
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
EP3062814A1 (en) * 2013-10-29 2016-09-07 Albumedix A/S Antibody composition
JP7156777B2 (ja) * 2013-11-29 2022-10-19 ジェネンテック， インコーポレイテッド 抗体選択装置及び方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
US20170002077A1 (en) * 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
AU2015270152A1 (en) * 2014-06-02 2016-12-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of Fc fragments
KR20170065662A (ko) * 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
AU2019251453A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
KR20220034169A (ko) * 2019-07-10 2022-03-17 리제너론 파아마슈티컬스, 인크. 감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물
AU2020337093B2 (en) * 2019-08-30 2025-02-27 Kashiv Biosciences, Llc Novel formulation of highly concentrated pharmacologically active antibody
CN113134081A (zh) * 2020-01-20 2021-07-20 上海君实生物医药科技股份有限公司 抗btla抗体药物组合物及其用途
WO2022092183A1 (ja) * 2020-10-30 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CA3198318A1 (en) 2020-11-14 2022-05-19 Yuan Zhao Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
JP2024513974A (ja) 2021-04-13 2024-03-27 バイオジェン・エムエイ・インコーポレイテッド 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS62196921A (ja) 1986-02-25 1987-08-31 Nec Corp 位相検出回路
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
NZ261250A (en) 1993-01-06 1997-08-22 Kinerton Ltd Ionic conjugates of polypeptides
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
EP2053961A4 (en) 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT

Also Published As

Publication number Publication date
EP2170390A2 (en) 2010-04-07
CA2690382A1 (en) 2008-12-24
AR067011A1 (es) 2009-09-30
IL202648B (en) 2018-04-30
WO2008157356A2 (en) 2008-12-24
PL2170390T3 (pl) 2019-05-31
US20130017193A1 (en) 2013-01-17
MX2020005214A (es) 2020-08-20
CN103977404A (zh) 2014-08-13
PT2170390T (pt) 2019-02-12
BRPI0814252B1 (pt) 2019-12-10
MX2009013593A (es) 2010-01-20
US9533044B2 (en) 2017-01-03
EP2170390B1 (en) 2018-11-07
NZ595526A (en) 2013-03-28
US20120134989A1 (en) 2012-05-31
EA020456B1 (ru) 2014-11-28
NZ582436A (en) 2012-06-29
BRPI0814252A2 (pt) 2015-04-14
AU2008266051A2 (en) 2010-02-25
DK2170390T3 (en) 2019-01-21
WO2008157356A3 (en) 2009-02-19
HRP20182146T1 (hr) 2019-02-08
CN101778640A (zh) 2010-07-14
IL202648A0 (en) 2011-08-01
AR117403A2 (es) 2021-08-04
US20080311119A1 (en) 2008-12-18
CY1121208T1 (el) 2020-05-29
EA201070015A1 (ru) 2010-06-30
AU2008266051B2 (en) 2014-07-31
BRPI0814252B8 (pt) 2021-05-25
TWI614028B (zh) 2018-02-11
JP2014040424A (ja) 2014-03-06
AU2008266051A1 (en) 2008-12-24
ES2707815T3 (es) 2019-04-05
SI2170390T1 (sl) 2019-02-28
LT2170390T (lt) 2019-01-10
EP3461500A1 (en) 2019-04-03
JP2010529999A (ja) 2010-09-02
TW200908995A (en) 2009-03-01
HUE041555T2 (hu) 2019-05-28
TR201820837T4 (tr) 2019-01-21

Similar Documents

Publication Publication Date Title
BRPI0814252A8 (pt) composição farmacêutica aquosa compreendendo natalizumab
BR112013007362A2 (pt) composição farmacêutica
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
BR112013004920A2 (pt) "composições pesticidas".
BR112012017051A2 (pt) método para diminuir a imunogenicidade
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
BR112013010320B8 (pt) Composições pesticidas.
UY30992A1 (es) Derivados de arilisoxazolina insecticidas
BR112013007577A2 (pt) conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
MX343625B (es) Composiciones plagicidas.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
UY33124A (es) Agentes y epítopos enlazados a wise
BRPI0909738A2 (pt) composições farmacêuticas aquosas contendo complexos de boratopoliol
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BR112015000329A2 (pt) formulações de diclofenac
PT1791571E (pt) Péptidos radiofluorados
UY31688A1 (es) Plaguicidas
EP2160407A4 (en) NEUTRALIZING ANTIBODIES
BRPI0919048B8 (pt) Composições pesticidas
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
BR112012002596A2 (pt) formulações de polipeptídeo concentradas com viscodidade reduzida
EP2400984A4 (en) HER2 ANTIBODY COMPOSITIONS

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25I Requirement for requested change of headquarter

Owner name: BIOGEN MA INC. (US)

B25G Requested change of headquarter approved

Owner name: BIOGEN MA INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF